🔗 Share this article

Given that the US continues making unprecedented revisions to its vaccine schedules, a particular individual has surfaced in a surprising turn: Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by expressing skepticism about COVID-19 vaccines during the pandemic and has focused upon alleged deaths following COVID-19 immunization in her brief time at the FDA.

Scheduled Shifts to Pediatric Vaccine Program

Agency leaders had intended to reveal sweeping changes to the childhood immunization program earlier this month, synchronizing the US with the Danish vaccine program, it is understood – a major change that would place the US out of alignment with a large portion of the international standard with no evidence for improved outcomes. This reveal has been postponed until the next year.

Instead of Vinay Prasad, Høeg is scheduled to present at the meeting. She was just designated acting director of the FDA’s CDER, the fifth appointee to head the division this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a strengthened alliance between the drug and vaccine centers as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon reevaluating long-standing immunizations at the FDA.

Høeg has often pushed for discontinuing specific childhood immunization guidelines in the US so as to align more in line with the Danish model, a society with universal health coverage and a number of inhabitants about the population of Wisconsin’s.

To date comments, she has kept her attention on vaccination policy – typically the responsibility of Dr. Prasad, director of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

The appointee has no obvious track record in pharmaceutical research, regulation or management, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, said Jonathan Howard. “She’s never run a scientific study. She lacks experience in managing a major agency. She is not an expert in drug approvals.”

Past commissioners of the center would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who led CBER have had.”

This division has an enormous portfolio at the FDA, the former commissioner pointed out.

“Many people just pays attention on the new drug program, but the generic program approves thousands of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and other areas, and all of those have to be managed,” Woodcock explained. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a major administrative element to the role, which supervises more than 5,000 employees. “It is a enormous leadership role, if you perform it correctly,” Woodcock said.

Response and Controversial Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this selection indicates greater collaboration among regulatory chiefs on immunizations, a spokesperson responded that the “questions stem from inaccurate presumptions”.

“Her resume matches the functions of her job,” the official said, pointing to the months Høeg spent advising the agency head on “drug safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's new priority voucher program, a contentious one-day therapy clearance system that apparently worried her former heads. “By what process are these medications being selected for this expedited pathway? Who takes the choices?” Howard said. “There is a lot of confidentiality happening at the regulatory body right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed oversight of all drugs, aside from shots.”

Established Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if troubling, history, some experts observe. She released a study using unverified volunteer-provided data to estimate the rate of heart inflammation after COVID-19 immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to indicate Covid vaccinations are riskier than they are.

Included in her “desired changes” for the new federal leadership featured revising guidelines for novel immunizations and discontinuing “optional” vaccines, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has reportedly proposed excluding young men from receiving COVID-19 vaccinations.

“She is an complete ideologue who commences with her conclusions and reverse-engineers to accommodate the data in a highly disingenuous, untruthful manner,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with fellow contrarians, {like|